Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlumosbart + SBRT + Chemo-immunotherapy in Advanced NSCLC With Bone Metastases
NCT06738160Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of narlumosbart in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 2 years. Started Feb 2025; status: recruiting.
02
Drugs
narlumosbart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06738160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738160.